Lipocine (LPCN)
(Delayed Data from NSDQ)
$3.02 USD
+0.05 (1.52%)
Updated Aug 13, 2025 03:41 PM ET
After-Market: $3.01 -0.01 (-0.17%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LPCN 3.02 +0.05(1.52%)
Will LPCN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LPCN based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for LPCN
Lipocine GAAP EPS of -$0.41, revenue of $0.62M
Lipocine (LPCN) Sees Significant Revenue Growth in Q2
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025 | LPCN Stock News
Lipocine reports Q2 EPS (41c) vs. (57c) last year
Lipocine Inc Reports Q2 2025 Earnings: EPS of ($0.41) Misses Estimates, Revenue of $0. ...